A Study to Assess Efficacy and Safety With VESIcare® to Improve Urinary Continence in Subjects After Robotic Assisted Radical Prostatectomy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01371994
First received: June 10, 2011
Last updated: November 11, 2013
Last verified: November 2013
  Purpose

The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of VESIcare® versus placebo in subjects who are incontinent after Robotic Assisted Radical Prostatectomy.

This study will also assess the effect of 12 weeks of treatment with VESIcare versus placebo on quality of life (QOL) as measured by questionnaires.


Condition Intervention Phase
Urinary Incontinence
Drug: solifenacin succinate
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • The time from the date of first dose to the date of urinary continence [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Urinary continence will be defined as the first of three consecutive 24 hour days which subject uses 0 pads, or a pad for security which remains completely dry, during the 12 week study


Secondary Outcome Measures:
  • Proportion of subjects who gain urinary continence [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to each month in average daily pad usage [ Time Frame: Baseline, 4 weeks, 8 weeks, and 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in quality of life (QOL) [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
    QOL as measured by the American Urology Association Symptom Score (AUASS)

  • Change from baseline in quality of life (QOL) [ Time Frame: Bsaeleine and 12 weeks ] [ Designated as safety issue: No ]
    QOL as measured by the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)

  • Change from baseline to end of study on work productivity [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
    Work productivity will be measured by the Work Productivity and Activity Impairment Questionnaire (WPAI)

  • Time from baseline to first day of returning to work [ Time Frame: Baseline and up to 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 629
Study Start Date: August 2011
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: solifenacin succinate Drug: solifenacin succinate
oral
Other Names:
  • Vesicare
  • YM905
Placebo Comparator: Placebo Drug: Placebo
oral

Detailed Description:

The study duration includes a 14-day treatment free wash-out period. The maximum total study duration is 15 weeks (2-3 week screening/washout period and a 12 week treatment period). The Baseline, Week 4, and Week 8 visits will be telephone contact visits.

Subjects will complete an electronic daily pad use diary during the study duration. Subjects will also be asked to complete several questionnaires during the study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is ambulatory
  • Subject is willing and able to complete the daily pad use diary, American Urology Association Symptom Score (AUASS) with Bother Score, the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF), and the Work Productivity and Activity Impairment Questionnaire (WPAI)
  • Subject has not used any medication for over-active bladder symptoms for at least 14 days prior to enrollment
  • Subject has been diagnosed with prostate cancer, treated by Robotic Assisted Radical Prostatectomy, is voiding spontaneously and has urinary incontinence one week after removal of the indwelling catheter which requires management with 2 to 10 pads inclusive per day (24 hour days) for 7 consecutive days

Exclusion Criteria:

  • Subject has evidence of severe neurologic damage post-prostatectomy
  • Subject has evidence of chronic urologic inflammation such as interstitial cystitis and bladder stone; uncontrolled narrow angle glaucoma; urinary or gastric retention or neurogenic bladder
  • Subject is symptomatic for urinary tract infection or has a urine culture result which requires treatment as determined by the investigator.
  • Subject has a clinically significant history of hepatic or renal impairment (2 X Upper Limit of Normal (ULN) values in ALT, AST or creatinine clearance < 30 ml/min)
  • Subject has history of diagnosed gastrointestinal obstruction disease
  • Subject has any prior history of local radiation therapy to the prostate or rectum or any prior hormonal therapy or has planned such therapy during study conduct
  • Subject has known or suspected hypersensitivity to solifenacin succinate, any components, or other anticholinergics
  • Subject has been treated with any investigational drug within last 30 days
  • Subject has a history of a clinically significant illness or medical condition that would preclude participation in the study
  • Subject has been diagnosed with New York Heart Association Class III and IV heart failure
  • Subject has the following peri-operative laboratory results: ALT > 2.0 ULN, AST > 2.0 ULN, serum creatinine > 1.5 mg/L, blood glucose > 130 mg/dL, BUN > 23 mg/dL.
  • Subject has severe hypertension on peri-operative evaluation which is defined as a sitting systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg, and which is not corrected
  • Subject has electrolytes (sodium, potassium, chloride or bicarbonate) that are not in normal range and clinically significant as determined by the investigator in the perioperative period. Subject can be eligible if electrolytes are corrected to within normal range prior to randomization
  • Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives, whichever is longer, prior to the initiation of Screening
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01371994

  Hide Study Locations
Locations
United States, Alabama
Urology Centers of Alabama
Homewood, Alabama, United States, 35209
United States, Alaska
Alaska Clinical Research Center
Anchorage, Alaska, United States, 99508
United States, Arizona
Urological Associates of Southern Arizona
Tucson, Arizona, United States, 85715
United States, California
University of California, San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Tower Urology
Los Angeles, California, United States, 90048
Radiological Associates of Sacramento Medical Group, Inc.
Sacramento, California, United States, 95815
United States, Colorado
Urology Center of Colorado
Denver, Colorado, United States, 80211
Urology Associates
Englewood, Colorado, United States, 80113
Advanced Urology
Parker, Colorado, United States, 80134
United States, Connecticut
Connecticut Clinical Research Center
Middlebury, Connecticut, United States, 06762
Grove Hill Medical Center
New Britain, Connecticut, United States, 06052
United States, District of Columbia
Urologic Surgeons of Washington
Washington, District of Columbia, United States, 20036
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
Urology Research Network
Hialeah, Florida, United States, 33016
East Coast Institute for Research
Jacksonville, Florida, United States, 32204
Winter Park Urology Associates
Orlando, Florida, United States, 32803
Southeastern Research Group
Tallahassee, Florida, United States, 32308
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Springfield Clinic
Springfield, Illinois, United States, 62703
United States, Indiana
Northeast Indiana Research
Fort Wayne, Indiana, United States, 46825
Urology of Indiana
Greenwood, Indiana, United States, 46143
United States, Iowa
The University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
The Iowa Clinic
West Des Moines, Iowa, United States, 50266
United States, Louisiana
Tulane University School of Medicine, Department of Urology
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
Lahey Clinic Medical Center
Burlington, Massachusetts, United States, 01805
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Spectrum Health Medical Group
Grand Rapids, Michigan, United States, 49546
United States, Minnesota
Adult and Pediatric Urology Group
Sartell, Minnesota, United States, 56377
United States, Montana
Five Valley Urology
Missoula, Montana, United States, 59808
United States, Nevada
South Nevada Aids Research
Las Vegas, Nevada, United States, 89106
United States, New Jersey
AdvanceMed Research
Lawrenceville, New Jersey, United States, 08648
Delaware Valley Urology
Mt. Laurel, New Jersey, United States, 08043
Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08901
United States, New York
Community Care Physicians PC
Albany, New York, United States, 12208
Brooklyn Urology Research Group
Brooklyn, New York, United States, 11215
University Urology Associates
New York, New York, United States, 10016
Hudson Valley Urology, PC
Poughkeepsie, New York, United States, 12601
University of Rochester Medical Center
Rochester, New York, United States, 14642
AMP Urology
Syracuse, New York, United States, 13210
United States, North Carolina
Cary Urology
Cary, North Carolina, United States, 27511
Associated Urologists of North Carolina
Raleigh, North Carolina, United States, 27607
United States, Ohio
The Urology Group
Cincinnati, Ohio, United States, 45212
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Romius Institute of Northwest Ohio
Toledo, Ohio, United States, 43615
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
Urologic Consultants of Southeastern Pennsylvania
Bala Cynwyd, Pennsylvania, United States, 19004
United States, Rhode Island
Pharma Resources
East Providence, Rhode Island, United States, 02915
United States, Tennessee
Academic Urologists
Chattanooga, Tennessee, United States, 37403
Volunteer Research Group
Knoxville, Tennessee, United States, 37920
Southeast Urology Network
Memphis, Tennessee, United States, 38119
United States, Texas
Urology Clinics of North Texas
Dallas, Texas, United States, 75231
Methodist Hospital Research Institute
Houston, Texas, United States, 77030
Methodist Urology Associates
Houston, Texas, United States, 77094
Urology San Antonio Research
San Antonio, Texas, United States, 78229
United States, Washington
Swedish Urology Group
Seattle, Washington, United States, 98104
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
United States, West Virginia
CAMC Institute Clinical Trial Center
Charleston, West Virginia, United States, 25304
United States, Wisconsin
University of Wisconsin Hospital
Madison, Wisconsin, United States, 53792
Canada, British Columbia
The Prostate Centre, Diamond Health Care Centre
Vancouver, British Columbia, Canada, V5Z IM9
Canada, Ontario
University Health Network/ Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Study Director: Medical Director Astellas Pharma Global Development
  More Information

No publications provided

Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT01371994     History of Changes
Other Study ID Numbers: 905-UC-050
Study First Received: June 10, 2011
Last Updated: November 11, 2013
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Astellas Pharma Inc:
Radical Robotic Arm
Post Prostatectomy Incontinence
Vesicare
YM905

Additional relevant MeSH terms:
Urinary Incontinence
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 22, 2014